Dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts.

On Thursday, August 7, Eli Lilly's stock (NYSE:LLY) dropped by 14%, even though the company announced a strong quarter with earnings, revenues, and guidance that exceeded market expectations. This ...

Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Acquisition aligns Lilly's ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse. A more ...

Eli Lilly has committed to setting a new standard for on-screen representation of common chronic diseases, and it walked the walk with its recent sponsorship of a segment on “Project Runway.” In the ...

Eli Lilly delivered strong Q2 results, raising full-year guidance, but shares plunged over 15% due to underwhelming Orforglipron weight loss data. Tirzepatide's explosive growth cements Lilly's ...

IT’S MORE THAN life-saving medicine. Lilly is a world premier medicine company, discovering innovative treatments to fight diseases like cancer, diabetes, and Alzheimer’s. Based in Indianapolis, Lilly ...

From in-depth workshops to networking opportunities, the 44th edition of the Original Lilly Conference on College Teaching has a little bit of everything for educators, no matter the experience level.

(Bloomberg) -- Eli Lilly & Co. halted a study of an experimental drug designed to prevent obesity patients from losing too much muscle, citing strategic business reasons it didn’t disclose. Lilly ...